What Comes After 23andMe for Consumer Genetics

Kian Sadeghi, founder and CEO of Nucleus Genomics, joins the show to unpack the fall of 23andMe and what its $256M acquisition by Regeneron means for the future of consumer DNA testing.

We talk about what 23andMe got wrong—from its business model to its reliance on outdated genotyping tech—and how a new generation of genomic startups like Nucleus are taking a different approach: full genome sequencing, HIPAA compliance, and consumer empowerment.

We also covered Klarna’s rising credit losses, JPMorgan’s AI-driven hiring slowdown, Waymo’s expansion into San Jose, and Zoox’s new test market in Atlanta.